Introduction

For decades, lung cancer has been closely associated with smoking. While tobacco use remains the leading cause of the disease, it is a common misconception that only smokers develop lung cancer.

In reality, thousands of people who have never smoked are diagnosed with lung cancer every year. Research has shown that factors such as air pollution, genetics, second-hand smoke, radon gas, occupational exposures, and certain genetic mutations can also contribute to the development of the disease.

Understanding these risks is essential because early detection and personalised treatment have significantly improved outcomes for many patients.

At CBMeds, a division of Curiance Biotech, we are committed to raising awareness about lung cancer and improving access to quality oncology medicines worldwide.

Smoking Is the Leading Risk Factor—But Not the Only One

Smoking is responsible for the majority of lung cancer cases, but it does not explain every diagnosis.

Studies suggest that 10–25% of lung cancer cases occur in people who have never smoked, making lung cancer one of the most common cancers diagnosed in non-smokers.

This highlights the importance of recognising other risk factors and seeking medical attention for persistent symptoms, regardless of smoking history.

Air Pollution and Lung Health

Air pollution is increasingly recognised as a significant contributor to lung disease.

Tiny airborne particles known as PM2.5 can penetrate deep into the lungs, causing long-term inflammation and damage.

Sources of air pollution include:

• Vehicle emissions
• Industrial pollution
• Construction dust
• Biomass burning
• Wildfire smoke

Although avoiding pollution completely may not be possible, reducing exposure where practical can support lung health.

Genetics Can Play a Role

Some people inherit genetic factors that may increase their susceptibility to cancer.

In addition, certain genetic changes within lung cancer cells—such as EGFR mutations, ALK rearrangements, or ROS1 fusions—help determine which targeted treatments may be effective.

This is why molecular testing has become a standard part of care for many patients with advanced non-small cell lung cancer (NSCLC).

Second-Hand Smoke

Exposure to tobacco smoke from family members, colleagues, or public places can also increase lung cancer risk.

Second-hand smoke contains many of the same harmful chemicals found in directly inhaled cigarette smoke.

Creating smoke-free homes and workplaces helps protect everyone.

Radon Gas

Radon is a naturally occurring radioactive gas that cannot be seen, smelled, or tasted.

It can accumulate in buildings, particularly in areas with certain geological conditions.

Long-term exposure to elevated radon levels has been associated with an increased risk of lung cancer.

Occupational Exposures

Some professions expose workers to substances linked to lung cancer.

Examples include:

• Asbestos
• Silica dust
• Diesel exhaust
• Arsenic
• Chromium
• Nickel compounds

Employers and workers should follow recommended workplace safety measures to reduce these risks.

Early Symptoms Should Never Be Ignored

Lung cancer often develops without obvious symptoms during its early stages.

Possible warning signs include:

• Persistent cough
• Chest pain
• Shortness of breath
• Coughing up blood
• Hoarseness
• Unexplained weight loss
• Fatigue
• Recurrent chest infections

These symptoms do not always indicate cancer, but they should be evaluated by a healthcare professional if they persist.

The Importance of Early Diagnosis

Early detection can improve treatment options and outcomes.

Depending on the stage and type of lung cancer, treatment may include:

• Surgery
• Radiation therapy
• Chemotherapy
• Immunotherapy
• Targeted therapy

Routine follow-up and prompt medical evaluation are especially important for individuals at higher risk.

Precision Medicine Is Changing Lung Cancer Care

Modern oncology focuses on treating cancer based on its molecular characteristics rather than its location alone.

Patients with advanced NSCLC are commonly tested for biomarkers such as:

• EGFR
• ALK
• ROS1
• BRAF
• MET
• RET
• KRAS

These tests help doctors identify patients who may benefit from targeted therapies.

Targeted Therapy for EGFR-Mutated Lung Cancer

For patients with EGFR-mutated NSCLC, targeted therapies such as Osimertinib have changed the treatment landscape.

Clinical studies have shown benefits including:

• Longer progression-free survival
• Better control of brain metastases
• Improved overall outcomes for many eligible patients
• Convenient once-daily oral treatment

Treatment selection should always be based on molecular testing and clinical evaluation by an oncologist.

Reducing Your Risk

While not every case of lung cancer can be prevented, you can help lower your risk by:

• Avoiding tobacco products
• Limiting exposure to second-hand smoke
• Reducing exposure to air pollution when possible
• Following workplace safety guidelines
• Maintaining a healthy lifestyle
• Seeking medical attention for persistent respiratory symptoms

How CBMeds Supports Patients Worldwide

CBMeds, a division of Curiance Biotech, supports patients, hospitals, and healthcare professionals by facilitating responsible international access to prescribed oncology medicines.

Our services include:

• Quality-assured medicine sourcing
• Regulatory documentation guidance
• International logistics support
• Patient assistance
• Healthcare professional coordination
• Support across 175+ countries

We are committed to helping improve access to quality cancer treatments while maintaining high standards of safety, transparency, and regulatory compliance.

Frequently Asked Questions

Can non-smokers develop lung cancer?

Yes. Lung cancer can occur in people who have never smoked due to factors such as air pollution, genetics, second-hand smoke, radon exposure, and occupational hazards.

Is smoking still the biggest risk factor?

Yes. Smoking remains the leading cause of lung cancer, but it is not the only cause.

Why is molecular testing important?

Molecular testing identifies genetic mutations that help doctors choose the most appropriate targeted treatment for eligible patients.

Can lung cancer be treated effectively?

Treatment depends on the stage, type of lung cancer, and molecular profile. Early diagnosis and personalised treatment have significantly improved outcomes for many patients.

Final Thoughts

Lung cancer is not just a smoker’s disease.

Although smoking remains the leading cause, many people who have never smoked are diagnosed each year due to a combination of environmental, occupational, and genetic factors.

Understanding these risks, recognising symptoms early, and taking advantage of advances in molecular testing and targeted therapy can make a meaningful difference in patient outcomes.

At CBMeds, a division of Curiance Biotech, we remain committed to supporting patients and healthcare professionals through education, responsible medicine access, and improved global oncology care.

About CBMeds

CBMeds, a division of Curiance Biotech, facilitates responsible international access to quality-assured oncology medicines. Supporting patients and healthcare providers in 175+ countries, we are committed to improving access to prescribed cancer treatments through compliant regulatory pathways and trusted global logistics.

Medical Disclaimer

This article is intended for educational purposes only and should not replace professional medical advice. Always consult a qualified healthcare professional regarding symptoms, diagnosis, screening, or treatment options.